1. Home
  2. HIHO vs MYNZ Comparison

HIHO vs MYNZ Comparison

Compare HIHO & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Highway Holdings Limited

HIHO

Highway Holdings Limited

HOLD

Current Price

$0.83

Market Cap

4.8M

Sector

Industrials

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.22

Market Cap

8.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIHO
MYNZ
Founded
1990
2021
Country
Hong Kong
Germany
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
8.8M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
HIHO
MYNZ
Price
$0.83
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
14.0K
188.9K
Earning Date
12-15-2025
12-29-2025
Dividend Yield
14.63%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,143,000.00
$659,935.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.82
$0.92
52 Week High
$2.05
$8.20

Technical Indicators

Market Signals
Indicator
HIHO
MYNZ
Relative Strength Index (RSI) 15.86 54.02
Support Level $1.12 $1.00
Resistance Level $1.28 $1.15
Average True Range (ATR) 0.07 0.08
MACD -0.03 0.03
Stochastic Oscillator 0.04 76.27

Price Performance

Historical Comparison
HIHO
MYNZ

About HIHO Highway Holdings Limited

Highway Holdings Ltd is a holding company. Along with its subsidiaries, it operates as a fully integrated manufacturer of high-quality metal, plastic, electric and electronic components, subassemblies, and finished products for OEMs and contract manufacturers. The manufacturing services offered by the group include metal stamping, screen printing, plastic injection molding, pad printing, and electronic assembly of printed circuit boards. Its reportable business segments are metal stamping and mechanical OEM operations, which derive maximum revenue, and electric OEM operations. Geographically, the group generates maximum revenue from Europe, and the rest from North America, Hong Kong and China, and other Asian countries.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: